boothwyn semaglutide ozempic #mounjaro #wegovy # Boothwyn | 503A Compounding Pharmacy

10.1212/CON.0000000000000943 151

doi:10.1007/bf02284971

A higher dose of Wegovy (7.2 mg) was approved by the MHRA in January 2026 following the STEP UP trial, which showed: 2 Wegovy 7.2 mg: 20.7% average weight loss Wegovy 2.4 mg: 17.5% average weight loss 50.9% of those on 7.2 mg lost at least 20% of body weight The 7.2 mg dose is not a starting dose

While we cannot reproduce clinical photographs from the cited studies without permission, we can describe what the published cases document: Patil and Mitra (2026) describe tongue hyperpigmentation in the context of Addison's disease - typically presenting as diffuse darkening of the tongue surface, often alongside pigmentation of other mucosal surfaces and skin creases

Lingappan K (2018) NF-B in Oxidative Stress